Get the Stockscreener App
2.69
2.89%
-0.08
After Hours:
2.72
0.03
+1.12%
Aclarion Inc stock is traded at $2.69, with a volume of 44,408.
It is down -2.89% in the last 24 hours and up +2.28% over the past month.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.
See More
Previous Close:
$2.77
Open:
$2.76
24h Volume:
44,408
Relative Volume:
0.66
Market Cap:
$7.75M
Revenue:
$77,900
Net Income/Loss:
$-8.05M
P/E Ratio:
-0.2915
EPS:
-9.2296
Net Cash Flow:
$-7.47M
1W Performance:
+12.08%
1M Performance:
+2.28%
6M Performance:
+5.91%
1Y Performance:
-61.84%
1-Day Range:
$2.64
$2.76
1-Week Range:
$2.36
$2.83
52-Week Range:
$1.95
$12.03
Aclarion Inc Stock (ACON) Company Profile
Name
Aclarion Inc
Sector
Industry
Phone
833 275 2266
Address
8181 ARISTA PLACE, BROOMFIELD
Compare ACON vs VEEV, TEM, BTSG, HQY, TXG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACON
Aclarion Inc
|
2.69 | 7.98M | 77,900 | -8.05M | -7.47M | -9.2296 |
VEEV
Veeva Systems Inc
|
250.53 | 40.77B | 3.32B | 941.65M | 1.64B | 5.6161 |
TEM
Tempus Ai Inc
|
66.65 | 11.05B | 1.36B | -302.91M | -219.93M | -1.7182 |
BTSG
Brightspring Health Services Inc
|
59.53 | 11.74B | 13.65B | 169.86M | 412.12M | 1.0758 |
HQY
Healthequity Inc
|
104.27 | 8.69B | 1.34B | 230.70M | 440.96M | 2.6695 |
TXG
10 X Genomics Inc
|
63.87 | 8.10B | 638.78M | -22.66M | 122.18M | -0.1744 |
Aclarion Inc Stock (ACON) Latest News
Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site - orthospinenews.com
Aclarion adds University of Arizona to Nociscan spine trial - Investing.com
Aclarion Announces Addition of University of Arizona College of MedicinePhoenix as CLARITY Trial Site - The Manila Times
Aclarion's 300-patient back-pain study now has 10 enrolling sites - Stock Titan
Aclarion (ACON) EPS and Revenue: The Available Earnings Metric Delivers a Miss in Latest Trading; After Results: The Stock Gains 6.54% on the DayROIC Trend Report - Vinanet
Aclarion director Amanda Williams buys $15,989 in common stock By Investing.com - Investing.com Nigeria
Aclarion director Amanda Williams buys $15,989 in common stock - Investing.com
Top Aclarion Executive Makes Bold Insider Move on Company Stock - TipRanks
Aclarion CFO Gregory Gould buys $24,500 of Aclarion stock By Investing.com - Investing.com Nigeria
Aclarion (ACON) Earnings Numbers in Focus: EPS Comes in Below Forecast under the Current Snapshot; Investor Response: The Market Price Declines 6.14% on the DayHealthcare Earnings Report - Vinanet
ACON | Aclarion, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Aclarion CFO Gregory Gould buys $24,500 of Aclarion stock - Investing.com
Major Insider Buying Spree Signals Strong Confidence in This Tech Stock - TipRanks
Aclarion director David K. Neal buys $18,000 in common stock By Investing.com - Investing.com Nigeria
Aclarion director David K. Neal buys $18,000 in common stock - Investing.com
Aclarion CEO Brent Ness buys $12,090 in company stock By Investing.com - Investing.com India
Aclarion director William Wesemann buys $5,031 in company stock - Investing.com
Aclarion director Ryan Bond buys $50,059 in ACON shares - Investing.com
Aclarion Inc. Warrant (ACONW) Jumps 21.95% to $0.03 as Support and Resistance ConvergeNarrow Range Breakout - dars.gov.et
Aclarion receives patent allowance for MRI scan technology By Investing.com - Investing.com Nigeria
Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process - The Manila Times
Aclarion Receives USPTO Notice of Allowance for Patent Covering Multi-Voxel Prescription for Lumbar Disc Evaluation - Quiver Quantitative
Aclarion receives patent allowance for MRI scan technology - Investing.com
Aclarion Receives Notice Of Allowance For Patent Advancing Accuracy And Adoption Of Nociscan's MR Spectroscopy Scan Process - marketscreener.com
Aclarion says USPTO issues notice of allowance for lumbar disc MRS scan-prescription patent application - Bitget
Aclarion Inc. (ACON) Slips 3.39% as Shares Approach Key $2.17 SupportTake Profit Levels - Vinanet
Aclarion, Inc. Revenue Breakdown – FWB:IT20 - TradingView
Aclarion, Inc. Revenue Breakdown – BOATS:ACONW - TradingView
Aclarion Inc (ACON) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aclarion, Inc. (ACON) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Aclarion, Inc. Q2 2026: Revenue $25.2K, EPS $(1.12) — 10-Q Summary - TradingView
Aclarion (NASDAQ: ACON) posts $5.6M H1 loss, holds $16.3M cash - Stock Titan
Tranche Update on Aclarion, Inc.'s Equity Buyback Plan announced on April 22, 2026. - marketscreener.com
Aclarion Q2 FY26 net loss narrows 59.27% to $2.75 million; revenue rises 30.5% to $25,208 - Bitget
Aclarion Inc. Warrant (ACONW) Slips 2.39% but Remains Supported at $0.02Resistance Breakout Stocks - dars.gov.et
Aclarion (ACON) Slips 1.69% to $2.32: Stock Presses Against Support at $2.20Strong Buy Stocks - dars.gov.et
Aclarion’s Nociscan Expands to Goodman Campbell Brain & Spine in First Indiana Site - Quiver Quantitative
Aclarion, Inc Announces Nociscan Now Available At Goodman Campbell Brain & Spine At Ascension St. Vincent - marketscreener.com
Aclarion Inc. Warrant (ACONW) Surges 35% to $0.03, Trading at Critical JunctureETF Inflow Streak - dars.gov.et
Aclarion Inc. Warrant (ACONW) Holds at $0.02 as Trading Range Compresses to a PointFibonacci Retracement - dars.gov.et
Aclarion Inc. Warrant (ACONW) Holds Steady at $0.02 as Trading Range CompressesReversal Trade - Vinanet
ACON Q1 2026 Earnings: EPS Exceeds Estimates by 15.2%, Shares Rise 11.4%Earnings Deceleration Risk - Vinanet
Aclarion Inc. Warrant (ACONW) Flat at $0.02 as Support and Resistance ConvergePrice Target - Vinanet
Aclarion reports 141% scan volume growth in first half of 2026 - Investing.com Nigeria
Aclarion Inc. (ACON) Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SentimentPost-Announcement Reaction - Vinanet
Aclarion, Inc. Revenue Breakdown – BOATS:ACON - TradingView
Aclarion Inc (ACON) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aclarion Inc (ACON) Institutional Confidence - TradingKey
Aclarion Inc (ACON) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aclarion Inc (ACON) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aclarion Inc (ACON) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aclarion Inc Stock (ACON) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aclarion Inc Stock (ACON) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gould Gregory A | CFO |
Aug 14 '26 |
Buy |
2.45 |
10,000 |
24,500 |
60,000 |
| Bond Ryan | Director |
Aug 13 '26 |
Buy |
2.37 |
21,122 |
50,059 |
76,122 |
| Wesemann William | Director |
Aug 13 '26 |
Buy |
2.34 |
2,150 |
5,031 |
23,713 |
| Neal David K | Director |
Aug 13 '26 |
Buy |
2.40 |
7,500 |
18,000 |
30,002 |
| Ness Brent | Chief Executive Officer |
Aug 13 '26 |
Buy |
2.31 |
5,234 |
12,091 |
111,534 |
| Breidbart Scott | Director |
May 12 '26 |
Buy |
3.18 |
5,664 |
18,012 |
5,664 |
| Neal David K | Director |
May 11 '26 |
Buy |
3.10 |
2,500 |
7,750 |
2,502 |
| Ness Brent | Chief Executive Officer |
May 11 '26 |
Buy |
3.18 |
6,289 |
19,999 |
6,300 |
| Wesemann William | Director |
May 06 '26 |
Buy |
3.30 |
1,562 |
5,155 |
1,563 |
| Ness Brent | Chief Executive Officer |
Nov 26 '25 |
Buy |
6.20 |
10 |
62 |
11 |
1.35%
2.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):